- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00440193
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Within the US 'Johnson & Johnson Pharmaceutical Research & Development, L.L.C.' is sponsor.
The treatment period was followed by an observational period of 30 days starting the day after the last intake of study medication, regardless of the actual duration of study drug administration. Participants who did not complete the treatment period also entered the observational period. It was also possible that participants did not enter the observational period, e.g. due to withdrawal of consent or termination of study participation. Participants who were transferring from study 11702 DVT (NCT00440193) to the extension study 11899 (NCT00439725) did not enter the observational period.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Australian Capital Territory
-
Garran, Australian Capital Territory, Australia, 2605
-
-
New South Wales
-
Darlinghurst, New South Wales, Australia, 2010
-
Gosford, New South Wales, Australia, 2250
-
Kogarah, New South Wales, Australia, 2217
-
Lismore, New South Wales, Australia, 2480
-
St Leonards, New South Wales, Australia, 2065
-
Sydney, New South Wales, Australia, 2031
-
Sydney, New South Wales, Australia, 2229
-
Sydney, New South Wales, Australia, 2139
-
-
Queensland
-
Brisbane, Queensland, Australia, 4029
-
Redcliffe, Queensland, Australia, 4020
-
Southport, Queensland, Australia, 4215
-
Woolloongabba, Queensland, Australia, 4102
-
-
South Australia
-
Adelaide, South Australia, Australia, 5042
-
Woodville South, South Australia, Australia, 5011
-
-
Victoria
-
Box Hill, Victoria, Australia, 3128
-
Clayton, Victoria, Australia, 3168
-
Geelong, Victoria, Australia, 3220
-
Melbourne, Victoria, Australia, 3135
-
Melbourne, Victoria, Australia, 3181
-
-
Western Australia
-
Fremantle, Western Australia, Australia, 6160
-
Perth, Western Australia, Australia, 6000
-
-
-
-
-
Innsbruck, Austria, 6020
-
Salzburg, Austria, 5020
-
Wien, Austria, 1090
-
Wien, Austria, 1140
-
-
Steiermark
-
Graz, Steiermark, Austria, 8036
-
-
Vorarlberg
-
Feldkirch, Vorarlberg, Austria, 6807
-
-
-
-
-
Bruxelles - Brussel, Belgium, 1070
-
Bruxelles - Brussel, Belgium, 1200
-
Duffel, Belgium, 2570
-
Genk, Belgium, 3600
-
Gent, Belgium, 9000
-
Hasselt, Belgium, 3500
-
Leuven, Belgium, 3000
-
Liege, Belgium, 4000
-
Lier, Belgium, 2500
-
Namur, Belgium, 5000
-
Yvoir, Belgium, 5530
-
Zottegem, Belgium, 9620
-
-
-
-
-
Rio de Janeiro, Brazil
-
-
Minas Gerais
-
Uberaba, Minas Gerais, Brazil, 38010 380
-
-
Parana
-
Curitiba, Parana, Brazil, 80050-350
-
Londrina, Parana, Brazil, 86038440
-
-
SP
-
Sao Paulo, SP, Brazil, 01509-900
-
Sao Paulo, SP, Brazil, 04023-061
-
São Paulo, SP, Brazil, 01323-001
-
-
Sao Paulo
-
Botucatu, Sao Paulo, Brazil, 18618 000
-
Sorocaba, Sao Paulo, Brazil, 18031-000
-
São Paulo, Sao Paulo, Brazil, 04039-004
-
-
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R2H 2A6
-
-
Ontario
-
London, Ontario, Canada, N6A 4G5
-
Ottawa, Ontario, Canada, K1Y 4E9
-
Toronto, Ontario, Canada, M4N 3M5
-
Toronto, Ontario, Canada, M6R 1B5
-
-
-
-
-
Beijing, China, 100044
-
Beijing, China, 100730
-
Beijing, China, 100020
-
Beijing, China, 100029
-
Beijing, China, 100037
-
Beijing, China, 100038
-
Beijing, China, 100853
-
Shanghai, China, 200032
-
Shanghai, China, 200001
-
Shanghai, China, 200433
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510120
-
Guangzhou, Guangdong, China, 510000
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150086
-
-
Hubei
-
Wuhan, Hubei, China, 430022
-
-
Jiangsu
-
Suzhou, Jiangsu, China, 215004
-
-
Liaoning
-
Shenyang, Liaoning, China, 110016
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310016
-
-
-
-
-
Karlovy Vary, Czech Republic, 360 00
-
Kladno, Czech Republic, 27259
-
Ostrava, Czech Republic, 728 80
-
Ostrava-Poruba, Czech Republic, 708 52
-
Prague, Czech Republic, 140 21
-
Prague 5, Czech Republic, 150 00
-
Praha 1, Czech Republic, 110 00
-
Praha 2, Czech Republic, 12800
-
Usti nad Lebem, Czech Republic, 401 13
-
-
-
-
-
Aarhus C, Denmark, 8000
-
Braedstrup, Denmark, 8740
-
Frederiksberg, Denmark, 2000F
-
Hellerup, Denmark, 2900
-
-
-
-
-
Seinäjoki, Finland, 60220
-
-
-
-
-
Agen Cedex 9, France, 47923
-
Amiens, France, 80000
-
Angers Cedex 01, France, 49033
-
Arras, France, 62000
-
Besancon, France, 25000
-
Bordeaux, France, 33000
-
Brest Cedex, France, 29609
-
Castelnau Le Lez, France, 34170
-
Clamart, France, 92141
-
Clermont Ferrand, France, 63000
-
Colombes Cedex, France, 92701
-
Creteil, France, 94000
-
Dijon, France, 21000
-
Grenoble, France, 38043
-
Grenoble, France, 38028
-
Lille Cedex, France, 59037
-
Limoges, France, 87042
-
Metz-tessy, France, 74370
-
Montpellier Cedex, France, 34295
-
Nantes, France, 44000
-
Nice, France, 06002
-
Nimes Cedex 9, France, 30029
-
Orthez, France, 64300
-
Paris, France, 75475
-
Paris, France, 75015
-
Paris, France, 75877
-
Paris, France, 75004
-
Paris Cedex 15, France, 75908
-
Pierre Benite, France, 69495
-
Roanne, France, 42328
-
Rouen Cedex, France, 76031
-
Saint Etienne, France, 42055
-
Strasbourg Cedex, France, 67091
-
Toulon, France, 83000
-
Toulouse, France, 31403
-
Tours, France, 37044
-
Valenciennes Cedex, France, 59322
-
Vandoeuvre Les Nancy, France, 54511
-
Vernon, France, 27200
-
-
-
-
-
Berlin, Germany, 10713
-
Berlin, Germany, 12099
-
Hamburg, Germany, 20251
-
-
Baden-Württemberg
-
Bruchsal, Baden-Württemberg, Germany, 76646
-
Heidelberg, Baden-Württemberg, Germany, 69115
-
Karlsbad, Baden-Württemberg, Germany, 76307
-
Mannheim, Baden-Württemberg, Germany, 68167
-
Neckargemünd, Baden-Württemberg, Germany, 69151
-
Tübingen, Baden-Württemberg, Germany, 72076
-
-
Bayern
-
Augsburg, Bayern, Germany, 86156
-
München, Bayern, Germany, 81377
-
München, Bayern, Germany, 80331
-
Würzburg, Bayern, Germany, 97080
-
-
Hessen
-
Darmstadt, Hessen, Germany, 64297
-
Frankfurt, Hessen, Germany, 60590
-
Frankfurt, Hessen, Germany, 60596
-
Gießen, Hessen, Germany, 35392
-
Wiesbaden, Hessen, Germany, 65183
-
-
Mecklenburg-Vorpommern
-
Greifswald, Mecklenburg-Vorpommern, Germany, 17475
-
-
Niedersachsen
-
Hannover, Niedersachsen, Germany, 30625
-
Rotenburg, Niedersachsen, Germany, 27342
-
-
Nordrhein-Westfalen
-
Düsseldorf, Nordrhein-Westfalen, Germany, 40225
-
Essen, Nordrhein-Westfalen, Germany, 45122
-
Paderborn, Nordrhein-Westfalen, Germany, 33098
-
Soest, Nordrhein-Westfalen, Germany, 59494
-
Witten, Nordrhein-Westfalen, Germany, 58455
-
-
Rheinland-Pfalz
-
Mainz, Rheinland-Pfalz, Germany, 55131
-
-
Saarland
-
Homburg, Saarland, Germany, 66424
-
Homburg, Saarland, Germany, 66421
-
-
Sachsen
-
Dresden, Sachsen, Germany, 01307
-
Leipzig, Sachsen, Germany, 04289
-
-
Sachsen-Anhalt
-
Halle, Sachsen-Anhalt, Germany, 06120
-
Magdeburg, Sachsen-Anhalt, Germany, 39112
-
-
-
-
-
Hong Kong, Hong Kong
-
Wanchai, Hong Kong
-
-
-
-
-
Budapest, Hungary, 1115
-
Budapest, Hungary, 1096
-
Debrecen, Hungary, 4032
-
Kecskemet, Hungary, 6000
-
Kistarcsa, Hungary, 2143
-
Miskolc, Hungary, 3526
-
Szentes, Hungary, 6600
-
Szombathely, Hungary, 9700
-
-
-
-
-
Hyderabad, India, 500082
-
Kolkata, India, 700029
-
New Delhi, India, 110060
-
Pune, India, 411001
-
-
Kerala
-
Kochi, Kerala, India, 682026
-
-
Maharashtra
-
Mumbai, Maharashtra, India, 400016
-
-
-
-
-
Bandung, Indonesia, 40161
-
Jakarta, Indonesia, 10430
-
Jakarta, Indonesia, 10330
-
Medan, Indonesia, 20152
-
Semarang, Indonesia, 50241
-
-
-
-
-
Afula, Israel, 18101
-
Ashkelon, Israel, 78306
-
Beer Sheva, Israel, 84101
-
Haifa, Israel, 31048
-
Haifa, Israel, 34362
-
Haifa, Israel, 31096
-
Holon, Israel, 58100
-
Jerusalem, Israel, 91120
-
Kfar Saba, Israel, 44281
-
Petach Tikva, Israel, 49100
-
Rehovot, Israel, 76100
-
Safed, Israel, 13100
-
Tel Aviv, Israel, 64239
-
-
-
-
-
Bologna, Italy, 40138
-
Chieti, Italy, 66013
-
Cremona, Italy, 26100
-
Milano, Italy, 20122
-
Milano, Italy, 20132
-
Milano, Italy, 20142
-
Napoli, Italy, 80131
-
Padova, Italy, 35128
-
Palermo, Italy, 90127
-
Parma, Italy, 43100
-
Pavia, Italy, 27100
-
Piacenza, Italy, 29100
-
Reggio Emilia, Italy, 42100
-
Varese, Italy, 21100
-
Venezia, Italy, 30122
-
-
-
-
-
Daegu, Korea, Republic of, 705-718
-
Daegu, Korea, Republic of, 700721
-
Seoul, Korea, Republic of, 137-701
-
Seoul, Korea, Republic of, 120-752
-
Taegu, Korea, Republic of, 700-712
-
-
Korea
-
Seoul, Korea, Korea, Republic of, 110-744
-
-
-
-
-
Selangor, Malaysia, 68000
-
-
-
-
-
Amsterdam, Netherlands, 1105 AZ
-
Arnhem, Netherlands, 6815 AD
-
Dordrecht, Netherlands, 3318 AT
-
Enschede, Netherlands, 7511 JX
-
Groningen, Netherlands, 9713 GZ
-
Hoofddorp, Netherlands, 2134 TM
-
Maastricht, Netherlands, 6229 HX
-
Rotterdam, Netherlands, 3083 AN
-
Zwijndrecht, Netherlands, 3331 LZ
-
Zwolle, Netherlands, 8025 AB
-
-
-
-
-
Auckland, New Zealand, 1023
-
Auckland, New Zealand, 2024
-
Auckland, New Zealand, 0622
-
Christchurch, New Zealand, 8011
-
Palmerston North, New Zealand, 4414
-
Wellington South, New Zealand, 6021
-
-
-
-
-
Fredrikstad, Norway, 1603
-
Oslo, Norway, 0407
-
Rud, Norway, 1309
-
Trondheim, Norway, 7006
-
-
-
-
-
Quezon City, Philippines, 1102
-
Quezon City, Philippines, 0850
-
-
-
-
-
Bialystok, Poland, 15-276
-
Bydgoszcz, Poland, 85-168
-
Gdansk, Poland, 80-952
-
Katowice, Poland, 40-365
-
Krakow, Poland, 31-066
-
Lodz, Poland, 90-153
-
Lublin, Poland, 20-081
-
Poznan, Poland, 60-631
-
Poznan, Poland, 61-848
-
Torun, Poland, 87-100
-
Warszawa, Poland, 01-138
-
Warszawa, Poland, 02-097
-
Warszawa, Poland, 04-479
-
Wroclaw, Poland, 51-124
-
Wroclaw, Poland, 50-326
-
-
-
-
-
San Juan, Puerto Rico, 00927
-
-
-
-
-
Singapore, Singapore, 169608
-
Singapore, Singapore, 308433
-
-
-
-
Cape
-
Cape Town, Cape, South Africa, 7500
-
-
Gauteng
-
Johannesburg, Gauteng, South Africa, 2132
-
Johannesburg, Gauteng, South Africa, 2191
-
Johannesburg, Gauteng, South Africa, 2193
-
Johannesburg, Gauteng, South Africa, 2157
-
Johannesburg, Gauteng, South Africa, 1724
-
Pretoria, Gauteng, South Africa, 0181
-
Pretoria, Gauteng, South Africa, 0084
-
Pretoria, Gauteng, South Africa, 0157
-
-
Western Cape
-
Cape Town, Western Cape, South Africa, 7460
-
Somerset West, Western Cape, South Africa, 7130
-
Worcester, Western Cape, South Africa, 6850
-
-
-
-
-
Barcelona, Spain, 08036
-
Barcelona, Spain, 08025
-
Girona, Spain, 17007
-
Madrid, Spain, 28034
-
Pamplona, Spain, 31008
-
-
Barcelona
-
Terrassa, Barcelona, Spain, 08221
-
-
Madrid
-
Alcorcón, Madrid, Spain, 28922
-
Fuenlabrada, Madrid, Spain, 28942
-
-
Valencia
-
Xàtiva, Valencia, Spain, 46800
-
-
-
-
-
Borås, Sweden, 501 82
-
Göteborg, Sweden, 416 85
-
Göteborg, Sweden, 413 45
-
Jönköping, Sweden, 551 85
-
Sundsvall, Sweden, 851 86
-
Västervik, Sweden, 593 81
-
-
-
-
-
Luzern, Switzerland, 6000
-
Zürich, Switzerland, 8091
-
-
Genève 14
-
Genéve 14, Genève 14, Switzerland, 1211
-
-
Graubünden
-
Chur, Graubünden, Switzerland, 7000
-
-
Waadt
-
Lausanne, Waadt, Switzerland, 1005
-
Lausanne, Waadt, Switzerland, 1011
-
-
-
-
-
Taichung, Taiwan, 40705
-
Taipei, Taiwan, 112
-
Taipei, Taiwan, 10016
-
Taipei, Taiwan, 220
-
-
Kaoshiong
-
Kaosiung, Kaoshiong, Taiwan, 807
-
-
-
-
-
Bangkok, Thailand, 10400
-
Bangkok, Thailand, 10700
-
Pathumwan, Bangkok, Thailand, 10330
-
-
-
-
-
London, United Kingdom
-
-
Devon
-
Plymouth, Devon, United Kingdom, PL6 8DH
-
-
Essex
-
Chelmsford, Essex, United Kingdom, CM1 5ET
-
-
Greater London
-
Isleworth, Greater London, United Kingdom, TW7 6AF
-
London, Greater London, United Kingdom, SE5 9RS
-
London, Greater London, United Kingdom, SE1 7EH
-
-
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
-
-
California
-
Redlands, California, United States, 92373
-
-
Florida
-
Bay Pines, Florida, United States, 33744
-
Miami, Florida, United States, 33136
-
Miami, Florida, United States, 33136-1096
-
-
Idaho
-
Idaho Falls, Idaho, United States, 83404
-
-
Louisiana
-
Covington, Louisiana, United States, 70433
-
-
Maryland
-
Baltimore, Maryland, United States, 21215
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87108-4763
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599-7035
-
Greensboro, North Carolina, United States, 27401
-
Greensboro, North Carolina, United States, 27403
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
-
-
Pennsylvania
-
Camp Hill, Pennsylvania, United States, 17011
-
Pittsburgh, Pennsylvania, United States, 15224
-
-
Texas
-
Corsicana, Texas, United States, 75110
-
San Antonio, Texas, United States, 78229
-
-
Utah
-
Murray, Utah, United States, 84157
-
Salt Lake City, Utah, United States, 84132
-
-
Virginia
-
Fredericksburg, Virginia, United States, 22401
-
-
Washington
-
Spokane, Washington, United States, 99204
-
Tacoma, Washington, United States, 98405
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Confirmed acute symptomatic proximal DVT without symptomatic PE
Exclusion Criteria:
- Legal lower age limitations (country specific)
- Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of DVT and/or PE
- Other indication for VKA than DVT and/or PE
- The pre-randomization anti-coagulant treatment (Criteria # 4) has been prolonged from 36 hours to a maximum of 48 hours.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Rivaroxaban (Xarelto, BAY59-7939)
Participants were to receive rivaroxaban 15 mg oral tablet twice daily for 3 weeks, followed by 20 mg once daily
|
During the first 3 weeks patients will receive 15 mg rivaroxaban twice-daily.
Thereafter, patients will receive rivaroxaban 20 mg once-daily.
Rivaroxaban will be administered orally and should be taken with food.
|
Active Comparator: Enoxaparin/VKA
Participants were to receive 1.0 mg/kg enoxaparin twice daily (subcutaneous) for at least 5 days, plus vitamin K antagonist (VKA) (oral) at individually titrated doses to achieve a target international normalized ratio (INR) of 2.5 (range: 2.0 to 3.0)
|
Enoxaparin 1.0 mg/kg twice daily with a minimal duration of 5 days.
This 5 days treatment could include the period up to 36 h before randomization if enoxaparin twice-daily was used.
VKA should be started as soon as possible but not later than 48 hours after randomization.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal Pulmonary Embolism [PE]) Until the Intended End of Study Treatment
Time Frame: 3-, 6- or 12-month study treatment period
|
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment.
Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), and/or case summaries.
|
3-, 6- or 12-month study treatment period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With the Composite Variable Comprising Recurrent DVT, Non-fatal PE and All Cause Mortality Until the Intended End of Study Treatment
Time Frame: 3-, 6- or 12-month study treatment period
|
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment.
Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries.
|
3-, 6- or 12-month study treatment period
|
Percentage of Participants With an Event for Net Clinical Benefit 1 Until the Intended End of Study Treatment
Time Frame: 3-, 6- or 12-month study treatment period
|
Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE, and major bleeding.
Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death.
Net clinical benefit was considered greater in those participants with fewer composite events.
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries.
|
3-, 6- or 12-month study treatment period
|
Percentage of Participants With Recurrent DVT Until the Intended End of Study Treatment
Time Frame: 3-, 6- or 12-month study treatment period
|
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment.
Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries.
|
3-, 6- or 12-month study treatment period
|
Percentage of Participants With Clinically Relevant Bleeding, Treatment-emergent (Time Window: Until 2 Days After Last Dose)
Time Frame: 3-, 6- or 12-month study treatment period
|
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment.
Clinically relevant bleeding included major bleeding (overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death) and non-major bleeding associated with medical intervention, unscheduled physician contact, (temporary) cessation of study treatment, discomfort for the participants such as pain, or impairment of activities of daily life.
|
3-, 6- or 12-month study treatment period
|
Percentage of Participants With All Deaths
Time Frame: 3-, 6- or 12-month study treatment period
|
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment.
Events were assessed based on either autopsy, results/films/images of confirmatory testing, and/or case summaries.
|
3-, 6- or 12-month study treatment period
|
Percentage of Participants With Other Vascular Events, On-treatment (Time Window: Until 1 Day After Last Dose)
Time Frame: 3-, 6- or 12-month study treatment period
|
All pre-defined vascular events (ST segment elevation myocardial infarction, non ST segment elevation myocardial infarction, unstable angina, ischemic stroke, transient ischemic attack, non-central nervous system systemic embolism or vascular death) were adjudicated and confirmed by a central independent adjudication committee blinded to treatment.
Events were assessed based results/films/images of confirmatory testing, and/or case summaries.
|
3-, 6- or 12-month study treatment period
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With the Individual Components of Efficacy Outcomes Until the Intended End of Study Treatment
Time Frame: 3-, 6- or 12-month study treatment period
|
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries.
Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death.
|
3-, 6- or 12-month study treatment period
|
Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal Pulmonary Embolism [PE]) During Observational Period
Time Frame: Up to 30 days after the last intake of study medication
|
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment.
Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), results/films/images of confirmatory testing, and/or case summaries.
|
Up to 30 days after the last intake of study medication
|
Percentage of Participants With the Composite Variable Comprising Recurrent DVT, Non-fatal PE and All Cause Mortality During Observational Period
Time Frame: Up to 30 days after the last intake of study medication
|
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment.
Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries.
|
Up to 30 days after the last intake of study medication
|
Percentage of Participants With an Event for Net Clinical Benefit 1 During Observational Period
Time Frame: Up to 30 days after the last intake of study medication
|
Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE or major bleeding.
Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death.
Net clinical benefit was considered greater in those participants with fewer composite events.
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries.
|
Up to 30 days after the last intake of study medication
|
Percentage of Participants With Recurrent DVT During Observational Period
Time Frame: Up to 30 days after the last intake of study medication
|
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment.
Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries.
|
Up to 30 days after the last intake of study medication
|
Percentage of Participants With the Individual Components of Efficacy Outcomes During Observational Period
Time Frame: Up to 30 days after the last intake of study medication
|
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries.
Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death.
|
Up to 30 days after the last intake of study medication
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010 Dec 23;363(26):2499-510. doi: 10.1056/NEJMoa1007903. Epub 2010 Dec 3.
- Cohen AT, Dobromirski M. The use of rivaroxaban for short- and long-term treatment of venous thromboembolism. Thromb Haemost. 2012 Jun;107(6):1035-43. doi: 10.1160/TH11-12-0859. Epub 2012 Feb 28.
- Prins MH, Lensing AW. Derivation of the non-inferiority margin for the evaluation of direct oral anticoagulants in the treatment of venous thromboembolism. Thromb J. 2013 Jul 6;11(1):13. doi: 10.1186/1477-9560-11-13.
- Prins MH, Lensing AW, Bauersachs R, van Bellen B, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Raskob GE, Berkowitz SD, Wells PS; EINSTEIN Investigators. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013 Sep 20;11(1):21. doi: 10.1186/1477-9560-11-21.
- Wang Y, Wang C, Chen Z, Zhang J, Liu Z, Jin B, Ying K, Liu C, Shao Y, Jing Z, Meng IL, Prins MH, Pap AF, Muller K, Lensing AW; Chinese EINSTEIN Investigators. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thromb J. 2013 Dec 16;11(1):25. doi: 10.1186/1477-9560-11-25.
- Bamber L, Wang MY, Prins MH, Ciniglio C, Bauersachs R, Lensing AW, Cano SJ. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thromb Haemost. 2013 Oct;110(4):732-41. doi: 10.1160/TH13-03-0243. Epub 2013 Jul 11.
- van Bellen B, Bamber L, Correa de Carvalho F, Prins M, Wang M, Lensing AW. Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Curr Med Res Opin. 2014 May;30(5):829-37. doi: 10.1185/03007995.2013.879439. Epub 2014 Jan 22.
- Cano SJ, Lamping DL, Bamber L, Smith S. The Anti-Clot Treatment Scale (ACTS) in clinical trials: cross-cultural validation in venous thromboembolism patients. Health Qual Life Outcomes. 2012 Sep 26;10:120. doi: 10.1186/1477-7525-10-120.
- Yang L, Wu J. Cost-effectiveness of rivaroxaban compared with enoxaparin plus warfarin for the treatment of hospitalised acute deep vein thrombosis in China. BMJ Open. 2020 Jul 30;10(7):e038433. doi: 10.1136/bmjopen-2020-038433.
- Ten Cate H, Lensing AWA, Weitz JI, Middeldorp S, Beyer-Westendorf J, Kubitza D, Brighton T, Raskob GE, Mismetti P, Prandoni P, Gebel M, Prins MH. The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients. Thromb Res. 2018 Oct;170:75-83. doi: 10.1016/j.thromres.2018.08.008. Epub 2018 Aug 15.
- Di Nisio M, Vedovati MC, Riera-Mestre A, Prins MH, Mueller K, Cohen AT, Wells PS, Beyer-Westendorf J, Prandoni P, Bounameaux H, Kubitza D, Schneider J, Pisters R, Fedacko J, Fontes-Carvalho R, Lensing AW. Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studies. Thromb Haemost. 2016 Sep 27;116(4):739-46. doi: 10.1160/TH16-02-0087. Epub 2016 Aug 18.
- Wells PS, Gebel M, Prins MH, Davidson BL, Lensing AW. Influence of statin use on the incidence of recurrent venous thromboembolism and major bleeding in patients receiving rivaroxaban or standard anticoagulant therapy. Thromb J. 2014 Nov 26;12:26. doi: 10.1186/1477-9560-12-26. eCollection 2014.
- Prins MH, Lensing AW, Brighton TA, Lyons RM, Rehm J, Trajanovic M, Davidson BL, Beyer-Westendorf J, Pap AF, Berkowitz SD, Cohen AT, Kovacs MJ, Wells PS, Prandoni P. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol. 2014 Oct;1(1):e37-46. doi: 10.1016/S2352-3026(14)70018-3. Epub 2014 Sep 28.
- Bauersachs RM, Lensing AW, Prins MH, Kubitza D, Pap AF, Decousus H, Beyer-Westendorf J, Prandoni P. Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment. Thromb J. 2014 Nov 24;12:25. doi: 10.1186/1477-9560-12-25. eCollection 2014.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Embolism and Thrombosis
- Thrombosis
- Venous Thrombosis
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Protease Inhibitors
- Factor Xa Inhibitors
- Antithrombins
- Serine Proteinase Inhibitors
- Anticoagulants
- Rivaroxaban
- Enoxaparin
Other Study ID Numbers
- 11702a
- 2006-004495-13 (EudraCT Number)
- 11702b (Company internal)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Venous Thrombosis
-
Hospital de Clinicas de Porto AlegreCompletedDeep Venous Thromboses | Deep Venous Thrombosis of Left Leg | Deep Venous Thrombosis of Right Leg | Deep Venous Thrombosis Proximal
-
Merit Medical Systems, Inc.CompletedChronic Venous Thrombosis | Venous Thrombosis Upper Extremity | Venous Thrombosis Upper Extremity Superficial VeinsAustria, Germany, Italy
-
Intermountain Health Care, Inc.TerminatedDeep Vein Thrombosis | Venous Thromboembolism | Deep Venous Thrombosis | Thrombus | Upper Extremity Deep Venous ThrombosisUnited States
-
Policlinico HospitalCompletedCentral Venous Catheter Thrombosis | Intensive Care Unit | Thrombosis, Venous | Central Venous CathetersItaly
-
Johns Hopkins UniversityPatient-Centered Outcomes Research InstituteCompletedVenous Thrombosis (Disorder)United States
-
University of Roma La SapienzaUnknownVenous Thromboembolism | Deep Venous ThrombosisItaly
-
The First Affiliated Hospital of Guangzhou Medical...CompletedDeep Venous Thrombosis
-
Russian Phlebological AssociationRecruitingVenous Insufficiency | Varicose Veins of Lower Limb | Thromboses, VenousRussian Federation
-
Tong ZhuNot yet recruitingDeep Vein Thrombosis | Deep Venous Insufficiency
-
Maastricht University Medical CenterTerminatedRandomized Clinical Trial | Deep-Venous Thrombosis | Deep Venous StentingNetherlands
Clinical Trials on Rivaroxaban (Xarelto, BAY59-7939)
-
BayerJanssen Research & Development, LLCCompletedCoronary Artery Disease | Cardiovascular DiseaseBelgium, Netherlands
-
BayerJanssen Research & Development, LLCCompletedVenous ThrombosisFrance, United States, Switzerland, Netherlands, Canada, Germany, Austria, Australia, Israel, Italy
-
BayerJanssen Research & Development, LLCCompletedNon-valvular Atrial FibrillationItaly
-
BayerJanssen Research & Development, LLCCompletedAtrial FibrillationAustria, Czechia, Hungary, Israel, Russian Federation, Slovakia, Slovenia, Germany, United Kingdom, France, Belgium, Canada, Netherlands, Poland, Denmark, Sweden, Portugal, Ireland, Norway, Moldova, Republic of, Ukraine
-
BayerJanssen Research & Development, LLC; RTI Health SolutionsCompletedAnticoagulationGermany, United Kingdom, France, Spain
-
BayerJanssen Research & Development, LLCCompleted
-
BayerJanssen Research & Development, LLCCompletedThrombosisCanada, United States, Belgium, Spain, Italy, France, Finland, Hungary
-
BayerJanssen Research & Development, LLCCompleted
-
BayerJanssen Research & Development, LLCCompletedVenous ThromboembolismSwitzerland, Spain, United States, Austria, Italy, Russian Federation, United Kingdom, Brazil, Australia, Canada, Hungary, Netherlands, Israel, Poland, Japan
-
BayerJanssen Research & Development, LLCCompletedAtrial FibrillationIndonesia, Korea, Republic of, Malaysia, Singapore, Thailand, Philippines, Taiwan, Hong Kong, India, Pakistan, Vietnam